Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF IRANIAN MEDICINE   MAY 2008 , Volume 11 , Number 3; Page(s) 247 To 251.
 
Paper: 

FREQUENCY OF BCR-ABL FUSION TRANSCRIPTS IN IRANIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

 
DOI: 

08113/AIM.003

 
Author(s):  YAGHMAEI MARJAN, GHAFARI S.H.A.*, GHAVAMZADEH ARDESHIR, ALI MOGHADAM K., JAHANI M., MOUSAVI S.A.A., IRAVANI M., BAHAR B., BIBORDI I.
 
* HEMATOLOGY-ONCOLOGY AND BONE MARROW TRANSPLANT RESEARCH CENTER, SHARIATI HOSPITAL, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

Background: A specific chromosomal abnormality, the Philadelphia chromosome, is present in 90 – 95% of patients with chronic myeloid leukemia. The aberration results from a reciprocal translocation of chromosomes 9 and 22, creating a BCR-ABL fusion gene. There are two major forms of the BCR-ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcript b2a2 or b3a2 codes for a p210 protein. Other fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 protein. Other less common fusion genes are b3a3 or b2a3 (p203) and e19a2 (p230). The incidence of one or other rearrangement in chronic myeloid leukemia patients varies in different reports. In general, fusion transcripts are determined individually, a process which is labor- intensive in order to detect all major fusion transcripts. The objective of this study was to set up a multiplex RT-PCR assay for detection and to determine the frequency of different fusion genes in 75 Iranian patients with chronic myeloid leukemia.
Methods: Peripheral blood samples were analyzed by multiplex RT-PCR from 75 adult Iranian chronic myeloid leukemia patients to detect different types of BCR-ABL transcripts of the t(9;22).
Results: All patients examined were positive for some type of BCR/ABL rearrangement. The majority of the patients (83%) expressed one of the p210BCR-ABL transcripts (b3a2, 62% and b2a2, 20%), while the remaining showed one of the transcripts of b3a3, b2a3, e1a2 or co-expression of b3a2 and b2a2. The rate of co-expression of the b3a2 and b2a2 was 5%.
Conclusion: In contrast to other reports, we did not see any co-expression of p210/p190. Coexpression may be due to alternative splicing or to phenotypic variation, with clinical course different from classic chronic myeloid leukemia.

 
Keyword(s): BCR-ABL, CHRONIC MYELOID LEUKEMIA, MULTIPLEX RT-PCR
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
 
+ Click to Cite.
APA: Copy

YAGHMAEI, M., & GHAFARI, S., & GHAVAMZADEH, A., & ALI MOGHADAM, K., & JAHANI, M., & MOUSAVI, S., & IRAVANI, M., & BAHAR, B., & BIBORDI, I. (2008). FREQUENCY OF BCR-ABL FUSION TRANSCRIPTS IN IRANIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. ARCHIVES OF IRANIAN MEDICINE, 11(3), 247-251. https://www.sid.ir/en/journal/ViewPaper.aspx?id=106044



Vancouver: Copy

YAGHMAEI MARJAN, GHAFARI S.H.A., GHAVAMZADEH ARDESHIR, ALI MOGHADAM K., JAHANI M., MOUSAVI S.A.A., IRAVANI M., BAHAR B., BIBORDI I.. FREQUENCY OF BCR-ABL FUSION TRANSCRIPTS IN IRANIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. ARCHIVES OF IRANIAN MEDICINE. 2008 [cited 2021July31];11(3):247-251. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=106044



IEEE: Copy

YAGHMAEI, M., GHAFARI, S., GHAVAMZADEH, A., ALI MOGHADAM, K., JAHANI, M., MOUSAVI, S., IRAVANI, M., BAHAR, B., BIBORDI, I., 2008. FREQUENCY OF BCR-ABL FUSION TRANSCRIPTS IN IRANIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. ARCHIVES OF IRANIAN MEDICINE, [online] 11(3), pp.247-251. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=106044.



 
  pdf-File
Yearly Visit 118
 
 
Latest on Blog
Enter SID Blog